European Archives - Page 1081 of 1163 - European Medical Journal

EMJ

Norgine Completes Agreement With Aspen For Its Southern African Operations And Product Rights

London. 30 September 2015, 14:00 BST. Norgine B.V. today announced that it has completed its agreement with Pharmacare Limited, a wholly owned subsidiary…

EMJ

Astellas European Foundation Grant Awarded to Look at Novel Molecular Imaging Techniques to Support Patients with Prostate Cancer

Chertsey, England [28th September, 2015] The 2015 Astellas European Foundation Uro‐Oncology Grant was awarded last night to a team led by…

EMJ

Large TAILORx Outcomes Study Demonstrates 99% of Patients with Low Oncotype DX® Recurrence Score® Results Were Breast Cancer Relapse-Free following Five Years of Hormone Therapy Alone

GENEVA, Switzerland, [September 28, 2015] – Genomic Health today announced the presentation of the first results1 from the Trial Assigning…

EMJ

Fractyl Announces Positive Results from 39-Patient Study of Revita DMR System

LONDON, UK AND WALTHAM, MA. – September 28, 2015 – Fractyl Laboratories, Inc. (Fractyl) today announced results from a 39-patient, single-site…

EMJ

Lifestyle Intervention Programme : Multidisciplinary Approach Increased Compliance by 450%

The Specialist Health Centre, an organisation working alongside the Essex primary and secondary care trusts, has recently responded to the demand for…

EMJ

Psychological Factors Affect Gastrointestinal Infections

ANXIETY increases the risk of gastrointestinal infection and long-term complications, according to the results of an investigation of a…

EMJ

Breakthrough Experimental Therapy Treats Colon Cancer and Chronic Inflammatory Bowel Disease

SCIENTISTS have discovered a groundbreaking experimental therapy that is capable of suppressing the development of ulcerative colitis (UC)…

EMJ

European CHMP Adopts Positive Opinion for Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV

Foster City, CA, September XX, 2015 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP)…

EMJ

NICE Recommends Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukaemia

London, 24 September 2015 – Gilead Sciences’ Zydelig® (idelalisib) has today been recommended by the National Institute for Health and Care Excellence…

EMJ

Gout Medications May Be Effective In Treating Alcohol-Induced Liver Disease

COMMONLY used gout medications could offer protection from alcohol-induced liver disease and inflammation, according to the results of new research in mice.